MyFinsight
Home
Blog
About
Marketable securities
$552M
(-16.74%↓ Y/Y)
Cash and cash
equivalents
$150M
(-39.52%↓ Y/Y)
Receivable from
collaboration partners
$36M
(140.00%↑ Y/Y)
Prepaid expenses and
other current assets
$18M
(-10.00%↓ Y/Y)
Total current assets
$756M
(-20.08%↓ Y/Y)
Long-term marketable
securities
$73M
(356.25%↑ Y/Y)
Other noncurrent
assets
$59M
(-14.49%↓ Y/Y)
Property and equipment,
net
$36M
(-18.18%↓ Y/Y)
Total assets
$924M
(-14.05%↓ Y/Y)
Total liabilities and
stockholders equity
$924M
(-14.05%↓ Y/Y)
Total stockholders
equity
$464M
(-15.48%↓ Y/Y)
Total current
liabilities
$198M
(-5.71%↓ Y/Y)
Other noncurrent
liabilities
$124M
(-22.01%↓ Y/Y)
Long-term debt
$101M
(4.12%↑ Y/Y)
Deferred revenue,
noncurrent (19 and 43 to a...
$37M
(-38.33%↓ Y/Y)
Accumulated deficit
-$1,704M
(-36.98%↓ Y/Y)
Accumulated other
comprehensive loss
-$1M
Common stock and
additional paid-in capital...
$2,169M
(20.97%↑ Y/Y)
Other current
liabilities
$145M
(31.82%↑ Y/Y)
Accounts payable (12 and
24 to a related...
$34M
(17.24%↑ Y/Y)
Deferred revenue (11 and
35 to a related...
$19M
(-73.24%↓ Y/Y)
Back
Back
Balance Sheet
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)
source: myfinsight.com